Global Spinal Muscular Atrophy Treatment Market Outlook to 2023 - The Development of New Innovative Therapies is Propelling Demand

DUBLIN, Nov. 19, 2018 /PRNewswire/ --

The "Global Spinal Muscular Atrophy Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The spinal muscular atrophy treatment market is projected to register a CAGR of almost 23% by 2023. With the increase in development of new innovative therapies, there is a growing demand for spinal muscular atrophy treatment.

The market is witnessing an increase in the development of new innovative therapies for the treatment of spinal muscular atrophy. For instance, two innovative new therapies for type 1 spinal muscular atrophy have proven to be highly effective in ongoing clinical trials. 

The first therapy employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh copy of the gene. The second therapy, which has already been approved by the FDA, is called nusinersen (SPINRAZA). It promotes the production of the nerve protein by SMN2.

These two therapies have improved the motor function in babies. AveXis in 2018, entered into a licensing agreement with Genethon for the in vivo gene therapy delivery of AAV9 vector into the CNS for the treatment of spinal muscular atrophy.

One trend affecting this market is the development of new innovative therapies for treatment. The market is witnessing an increase in the development of new innovative therapies for the treatment of spinal muscular atrophy. For instance, two innovative new therapies for type 1 spinal muscular atrophy have proven to be highly effective in ongoing clinical trials.

According to the report, one driver influencing this market is the rising number of initiatives being taken by organizations to provide patient care. Several organizations are taking initiatives to provide the best care to patients suffering from spinal muscular atrophy, and some organizations such as Cure SMA are offering care packages and family support staff to newly diagnosed patients.

Further, the report states that one challenge affecting this market is the low adoption of spinal muscular atrophy treatment. One of the major challenges faced in the market is low adoption of spinal muscular atrophy drug therapy as patients have a higher propensity towards other approaches, such as physiotherapy, nutritional support, respiratory care, and enablement strategies.

The market appears to be highly concentrated and with the presence of Biogen, the market is expected to grow less concentrated with the emergence of new players during the forecast period. Factors such as increase in development of new innovative therapies and rising number of initiatives being taken by organizations to provide patient care, will provide considerable growth opportunities to spinal muscular atrophy treatment companies. Biogen is the major company covered in this report.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

• Pipeline analysis
• PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY TYPE

• Market segmentation by type
• Comparison by type
• Type 2 - Market size and forecast 2018-2023
• Type 3 - Market size and forecast 2018-2023
• Type 1 - Market size and forecast 2018-2023
• Type 4 - Market size and forecast 2018-2023
• Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TREATMENT

• Segmentation by treatment

PART 10: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 13: MARKET TRENDS

• Rising awareness of treatment and diagnosis of spinal muscular atrophy
• Development of new innovative therapies for treatment
• Advances in diagnostic techniques

PART 14: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 15: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Biogen

For more information about this report visit https://www.researchandmarkets.com/research/6jb4d4/global_spinal?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-spinal-muscular-atrophy-treatment-market-outlook-to-2023---the-development-of-new-innovative-therapies-is-propelling-demand-300753062.html

SOURCE Research and Markets